DIA Biosimilars 2013

University of Texas

Neurodegeneration Consortium receives $5 million from Huffington Foundation

Wednesday, August 21, 2013 11:02 AM

The Huffington Foundation has committed $5 million to the Neurodegeneration Consortium (NDC), a multi-institutional collaboration to study and treat Alzheimer’s and other neurodegenerative diseases.

More... »

Cenduit: Now with Patient Reminders

Aeterna Zentaris announces first patient dosed in phase III endometrial cancer trial

Friday, August 9, 2013 02:05 PM

Aeterna Zentaris has announced the first patient has been recruited and dosed for the phase III ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

More... »

CRF Health – eCOA Forum

MCRC Launches Niche Phase I Business

Friday, December 26, 2008 08:00 AM

While the weakening economy has forced some drug companies to cancel or delay early phase projects, at least one company has seen a growing need for its niche phase I drug development services.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs